Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pulmatrix stock in Canada | $0.931

Own Pulmatrix shares in just a few minutes.

Pulmatrix, Inc
-$0.0002 (-0.02%)

Pulmatrix is a biotechnology business based in the US. Pulmatrix stocks (PULM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.948 – an increase of 1.53% over the previous week. Pulmatrix employs 20 staff and has a trailing 12-month revenue of around $11.3 million.

How to buy Pulmatrix stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: PULM in this case.
  5. Research Pulmatrix stocks. The platform should provide the latest information available.
  6. Buy your Pulmatrix stocks. It's that simple.

How has Coronavirus impacted Pulmatrix's stock price?

Since the stock market crash in March caused by coronavirus, Pulmatrix's stock price has had significant negative movement.

Its last market close was $0.931, which is 39.55% down on its pre-crash value of $1.54 and 3.44% up on the lowest point reached during the March crash when the stocks fell as low as $0.9.

If you had bought $1,000 worth of Pulmatrix stocks at the start of February 2020, those stocks would have been worth $778.44 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $557.48.

Pulmatrix stock price

Use our graph to track the performance of PULM stocks over time.

Pulmatrix stocks at a glance

Information last updated 2021-07-30.
Latest market close$0.931
52-week range$0.82 - $2.21
50-day moving average $0.9685
200-day moving average $1.2148
Wall St. target price$5
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.467

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Pulmatrix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Pulmatrix price performance over time

Historical closes compared with the last close of $0.931

1 month (2021-07-01) -8.73%
3 months (2021-04-30) -2.00%

Pulmatrix financials

Revenue TTM USD$11.3 million
Gross profit TTM USD$-2,975,000
Return on assets TTM -11.44%
Return on equity TTM -58.9%
Profit margin -166.28%
Book value $1.007
Market capitalisation USD$47.6 million

TTM: trailing 12 months

How to short and sell Pulmatrix stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "PULM.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 632,515 Pulmatrix stocks held short by investors – that's known as Pulmatrix's "short interest". This figure is 14.3% down from 737,633 last month.

There are a few different ways that this level of interest in shorting Pulmatrix stocks can be evaluated.

Pulmatrix's "short interest ratio" (SIR)

Pulmatrix's "short interest ratio" (SIR) is the quantity of Pulmatrix stocks currently shorted divided by the average quantity of Pulmatrix stocks traded daily (recently around 433229.45205479). Pulmatrix's SIR currently stands at 1.46. In other words for every 100,000 Pulmatrix stocks traded daily on the market, roughly 1460 stocks are currently held short.

However Pulmatrix's short interest can also be evaluated against the total number of Pulmatrix stocks, or, against the total number of tradable Pulmatrix stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pulmatrix's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Pulmatrix stocks in existence, roughly 10 stocks are currently held short) or 0.012% of the tradable stocks (for every 100,000 tradable Pulmatrix stocks, roughly 12 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Pulmatrix.

Find out more about how you can short Pulmatrix stock.

Pulmatrix stock dividends

We're not expecting Pulmatrix to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Pulmatrix stocks ever split?

Pulmatrix stocks were split on a 1:10 basis on 6 February 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pulmatrix stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for Pulmatrix stocks which in turn could have impacted Pulmatrix's stock price.

Pulmatrix stock price volatility

Over the last 12 months, Pulmatrix's stocks have ranged in value from as little as $0.82 up to $2.21. A popular way to gauge a stock's volatility is its "beta".

PULM.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulmatrix's is 1.3841. This would suggest that Pulmatrix's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Pulmatrix overview

Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site